Clinical Safety

When a lifesaving transplant risks unleashing the very immune fire meant to cure leukemia, choices about how to steer immunity before donor cells arrive determine whether patients heal or face harm. That dilemma sits at the heart of allogeneic hematopoietic stem cell transplantation, where

Glioblastoma care has long run up against a biological wall that blunts even the best therapies, and a new approach that pries open that wall just long enough to let drugs in now looks like a genuine shift rather than a lab curiosity. Patients still face a dire prognosis despite aggressive surgery

If bacteria aren’t the whole story of the tumor microenvironment, what crucial signals are being missed from fungi that quietly occupy the same space yet account for only a sliver of the sequencing reads but a disproportionate share of immune cues and clinical outcomes? That challenge has gained

Could a single seed pull double duty against inflammation, oxidative stress, microbes, and metabolic drift without the side-effect ledger that shadows many prescriptions, and could it do so in a way that complements rather than competes with standard care? That is the provocation driving a surge of

In a world where a stroke strikes someone every 40 seconds, the fear of a second, potentially fatal event looms large for millions of survivors, creating an urgent need for better solutions. Picture a patient, just recovered from an initial stroke, grappling with the uncertainty of whether their

I'm thrilled to sit down with Dr. Ivan Kairatov, a renowned expert in pediatric medicine with a focus on liver transplantation and patient-reported outcomes. With years of experience in research and innovation, Dr. Kairatov has been at the forefront of shifting how we understand children's